Testing Hypofractionated radiotherapy for esophageal cancer

Exclusion

• −Past or current history of malignancy other than entry diagnosis except for non-melanomatous skin cancer, or curatively treated carcinoma in situ of the cervix or a cured malignancy more than 5 years prior to enrollmentEnrolmentThe number of participants a study plans to include, or has included.Read more →
• −New York heart Association Class III/IV and no history of active angina. Documented myocardial infarction within the 6 months preceding registration (pretreatment echocardiogram evidence of infarct only will not exclude patients). Patients with a history of significant ventricular arrhythmia requiring medication or congestive heart failure. History of 2nd or 3rd degree heart blocks
• −Pre-existing motor or sensory neurotoxicity greater than WHO grade 1
• −Active infection or other serious underlying medical condition which would impair the ability of the patient to receive the planned treatment
• −Dementia or altered mental status that would prohibit the understanding and giving of informed consentInformed consentThe process of being told what taking part involves, then choosing freely.Read more →
• −Weight loss \> 20% within 3 months of the date of screeningScreeningThe checks done before joining, to see whether a study fits.Read more →
• −Esophageal stent
• −Patients unfit for any treatment component, including absolute contraindications for radiotherapy or Connective Tissue Disease.
• −Unable to complete surveys in English without aid of interpreter.
• −Pregnant or lactating patients; women of childbearing potential must have a negative serum pregnancy test within 7 days of Treatment Visit 1. Women or men of childbearing potential must use effective contraception (defined by the use of two birth controlControl groupThe group a new treatment is measured against.Read more → methods, which can be either two barrier methods or a barrier method plus a hormonal method to prevent pregnancy). Subjects must start using birth control from the time they have signed the Informed Consent Form prior to start of therapy until 120 days post completion of study therapy or study discontinuation, which must be documented in the eCRF.
• −Previous chemotherapy and radiotherapy